Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 11, 2006

GSK Submits SDA for Advair in COPD

  • GlaxoSmithKline submitted a supplemental new drug application to expand labeling for Advair Diskus® (fluticasone propionate and salmeterol inhalation powder), based on studies that showed reduced death risk and rate of chronic obstructive pulmonary disease (COPD) exacerbations.

    Results from GSK’s three-year TORCH study (TOwards a Revolution in COPD Health) showed a 17.5% reduction in risk of death from any cause over three years for patients receiving Advair 500/50 as compared with patients on placebo(p=0.052). In addition, it reduced the rate of COPD exacerbations by 25% compared with placebo (p<0.001). Advair also improved quality of life when compared to placebo (p<0.001), although it did not meet the predefined magnitude of difference.

    The company observed, however, that Advair was associated with increased reporting of pneumonia compared with placebo (p<0.001). Other adverse events (e.g. candidiasis, dysphonia, contusion) generally appear consistent with those seen in previous studies of Advair in patients with COPD.

    Advair 250/50 is currently indicated for the maintenance treatment of airflow obstruction in patients with COPD associated with chronic bronchitis.



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »